AN2 Therapeutics, Inc. (ANTX)
NASDAQ: ANTX · Real-Time Price · USD
1.100
+0.035 (3.29%)
At close: Dec 5, 2025, 4:00 PM EST
1.080
-0.020 (-1.82%)
After-hours: Dec 5, 2025, 7:29 PM EST
AN2 Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Selling, General & Admin | 14.11 | 14.07 | 14.76 | 12.75 | 4.67 | 1.27 | |
| Research & Development | 23.29 | 40.49 | 54.87 | 29.51 | 16.91 | 6.02 | |
| Operating Expenses | 37.4 | 54.55 | 69.64 | 42.26 | 21.57 | 7.28 | |
| Operating Income | -37.4 | -54.55 | -69.64 | -42.26 | -21.57 | -7.28 | |
| Interest & Investment Income | 3.41 | 5.47 | 4.86 | - | 0.07 | 0 | |
| Currency Exchange Gain (Loss) | - | - | - | - | -0.04 | - | |
| Other Non Operating Income (Expenses) | -0 | - | 0.04 | 1.31 | - | -6.32 | |
| EBT Excluding Unusual Items | -34 | -49.09 | -64.73 | -40.96 | -21.54 | -13.6 | |
| Merger & Restructuring Charges | 0.01 | -2.23 | - | - | - | - | |
| Pretax Income | -33.99 | -51.32 | -64.73 | -40.96 | -21.54 | -13.6 | |
| Net Income | -33.99 | -51.32 | -64.73 | -40.96 | -21.54 | -13.6 | |
| Preferred Dividends & Other Adjustments | - | - | - | 1.82 | 6.52 | 0.98 | |
| Net Income to Common | -33.99 | -51.32 | -64.73 | -42.78 | -28.06 | -14.58 | |
| Shares Outstanding (Basic) | 30 | 30 | 24 | 15 | 3 | 3 | |
| Shares Outstanding (Diluted) | 30 | 30 | 24 | 15 | 3 | 3 | |
| Shares Change (YoY) | 0.97% | 26.39% | 53.85% | 481.46% | 2.71% | 0.61% | |
| EPS (Basic) | -1.13 | -1.72 | -2.74 | -2.79 | -10.64 | -5.68 | |
| EPS (Diluted) | -1.13 | -1.72 | -2.74 | -2.79 | -10.64 | -5.68 | |
| EBIT | -37.4 | -54.55 | -69.64 | -42.26 | -21.57 | -7.28 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.